In prostate cancer, epigenetic silencing of the crucial component JAK1 kinase of the IFNγ signaling pathway led to IFNγ-insensitivity-mediated tumor evasion and resistance to immunotherapy [110]. The gene discussed is IFNG; the disease is prostate carcinoma.